ROS1 (6q22.1) BA

Intended Use
Chromosomal rearrangements involving the ROS1 gene were originally described in glioblastomas, where ROS1 is fused to the GOPC gene by an interstitial deletion. Fusions of ROS1 with other genes lead to constitutive kinase activity and are associated with in vitro sensitivity to tyrosine kinase inhibitors such as crizotinib.
Patient Preparation
  • Sample collection: Tumour Tissue Block
  • Specimen preparation: Do not freeze or expose to extreme temperatures.
  • FFPE Tissue Block: Formalin fix (10 percent neutral buffered formalin) and paraffin-embed tissue (3–4-micron thick sections in positively charged/silanized slides). Fixative duration: 6-48 hours.
  • Storage/Transport Temperature: Room temperature.
  • Unacceptable Conditions: Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens. Specimens with fixation delayed for more than one hour. Tissue fixed or less than 6 hours of greater than 48 hours.
  • Remarks:
  • Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology

Fluorescence in situ Hybridization (FISH)

Sample received to report Turnaround time (TAT)

3 working days

Reference Interval

————-

Interpretive Data

The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluation.

Resources

Sample Reports